Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC


Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Sirtex Medical, we had the pleasure of speaking with Mike Cusnir, MD, chief of the Division of Hematology & Oncology and co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, to discuss the use of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in metastatic colorectal cancer (CRC).

Chemotherapy can be effective in all lines of therapy for patients with CRC, but it can also produce high toxicities. Current research is investigating treatment options using Y-90 resin for patients that would allow them to avoid some of the toxicities associated with chemotherapy while increasing their treatment tolerance and prolonging their survival.

Y-90 resin shows potential as a maintenance therapy in patients with CRC that is localized in the liver who are looking to de-escalate chemotherapy. The microspheres can be leveraged in selective internal radiation therapy, where precise disease management is crucial.

In our exclusive interview, Dr Cusnir reviewed the benefits of isolating the liver in early CRC treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.

Thank you for listening to this episode of OncLive On Air®, sponsored by Sirtex Medical. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Chun Chao, PhD, MS
Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2
Richard Kim, MD
Salman R. Punekar, MD
Chun Chao, PhD, MS
Christos Kyriakopoulos, MD
Marwan G. Fakih, MD
John L. Marshall, MD
Rene Adam, MD, PhD
Amin Nassar, MD